Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders in CTEPH: The IPES Trial (IPES)

Impact of Pulmonary Endarterectomy on Sleep-Related Breathing Disorders and Mortality in Chronic Thromboembolic Pulmonary Hypertension - The IPES Trial: A Prospective, Observational, Cohort Study

Pulmonary hypertension (PH) has three main types, pre-capillary PH, post-capillary PH, and combined pre-capillary and post-capillary PH, and it is based on mean pulmonary arterial pressure (PAP) > 20 mmHg measured with a right heart catheterization (RHC).

Chronic thromboembolic pulmonary hypertension (CTEPH) is mainly defined as a pre-capillary PH and classed as a Group IV PH. It was reported that 0.1-9.1% of individuals with pulmonary embolism develop CTEPH within two years after the initial diagnosis, and CTEPH is the only PH category that has a chance of being cured, mainly by pulmonary endarterectomy.

Sleep-related breathing disorders (SRBD) are defined as obstructive sleep apnea (OSA) disorders, central sleep apnea (CSA) syndromes, sleep-related hypoventilation disorders, and sleep-related hypoxemia.

An SRBD may also lead to an increase in PAP primarily during sleep and cause nocturnal hypoxemia. Although SRBDs were reported in patients with pre-capillary PH, most of the studies included patients with idiopathic PAH. Although the cause-and-effect relationship between pre-capillary PH and SRBDs is uncertain, it is known that mPAP may increase during sleep in patients with OSA .

Less is known regarding the occurrence of SRBDs in CTEPH. Previously a few study showed relationship between SRBDs an CTEPH as the main type was OSA. Most of the studies evaluated preoperative occurance and incidance of SRBDs in CTEPH. Only one study performed post operative SRBD on a cardiorespiratory device was conducted the night before and one month after elective pulmonary endarterectomy.

In our previous study we showed that severe nocturnal hypoxemia (NH) is highly prevelant in preoperative CTEPH patients and the most common two types of SRBD are OSA and isolated sleep related hypoxemia (ISRH) and age, mPAP and AHI are independent determinants of severe NH. (J. Clin. Med. 2023, 12, 4639 https://doi.org/10.3390/jcm12144639) In this present study we aimed to investigate occurrence of SRBDs and mortality 5 years after pulmonary endarterectomy operation.

Study Overview

• Status: Not yet recruiting
• Conditions: Sleep-Disordered Breathing; Chronic Thromboembolic Pulmonary Hypertension; Post Operative
• Intervention / Treatment: Procedure: Pulmonary endarterectomy

Detailed Description

This study planned as continuation study of ''Determinants of severe nocturnal hypoxemia in adults with chronic thromboembolic pulmonary hypertension and sleep related breathing disorders'' J. Clin. Med. 2023, 12, 4639 https://doi.org/10.3390/jcm12144639

Previously included patients (50 patients who were referred for pulmonary endarterectomy operation between 5 May 2017 and 7 February 2018

• All participants underwent a computerized pulmonary angiography and RHC after that mismatch of perfusion defects detected in ventilation/perfusion scintigraphy (V/Q) despite 3 months of anticoagulant therapy.
• Patients with an mPAP > 20 mmHg measured with RHC were accepted having CTEPH PAWP≤15mmHg and PVR≥ 3 Wood Units were additional measurements suggestive of CTEPH.
• Eligible for surgery

• Appropriate polisomnography test before surgery

  • Total sleep time should be >4 hours) planned to include current study

    1. Demographic data, body mass index (BMI), comorbid conditions, medications, supplementary oxygen treatment, preoperative echocardiography findings, RHC measurements, 6 min walk distance (SMWD), pulmonary function test, as well as carbon monoxide diffusion test (DLCO) measurements will be recorded

       **MIR Spirolab II spirometry (Medical International Research, Rome, Italy) was used to test pulmonary function, including forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), diffusing capacity of the lung for DLCO in a body plethsmograph (CareFusion Type MasterScreen PFT, Hoechberg, Germany), and performance of an SMWD. All results were assessed in accordance with ATS recommendations

    2. A polisomnography test will perfomed to all participants (whether had pulmonary endarterectomy operation or followed up by medical treatment)

       • All patients will hospitalized for polysomnographic monitoring using the NOX- A1 system (Nox Medical Inc., Reykjavik, Iceland). The PSG recording included an elec- troencephalogram (F4/M1, F3/M2, C4/M1, C3/M2, O2/M1, O1/M2), electro-oculogram, submental and tibialis electromyograms, as well as an electrocardiogram. Ventilatory monitoring included a nasal pressure detector using a nasal cannula/pressure transducer system and thoracoabdominal movement detection through two respiratory inductance plethysmography belts. A finger pulse oximeter detecting heart rate, SpO2, as well as body position and movement detection will also include. Participants with a total sleep time of less than 4 h will be offered a new PSG. Sleep stages and arousals will score based on 30 s epochs in accordance with The AASM Manual for the Scoring of Sleep and Associated Events 2.5 published by the American Academy of Sleep Medicine (AASM), independently of the patients' clinics, by a certified sleep physician. Apnea will define as an almost complete (≥ 90%) cessation of airflow, and hypopnea will define as a decrease in nasal pressure amplitude of 30% or more and/or thoraco-abdominal movement of at least 30% for at least 10 s if there will be a significant oxyhemoglobin desaturation (reduction of at least 3% from the immediately preceding baseline value) and/or arousal, according to the latest recommendations of the AASM
       • SRBDs defined according to the International Classification of Sleep Disorders (ICSD)-10 as obstructive sleep apnea (OSA; as an AHI ≥ 15 events/h), central sleep apnea with Cheyne-Stokes respiration (CSA-CSR; CSR pattern ≥ 50% of total sleep time with , (TST)), obesity hypoventilation syndrome (OHS), and isolated sleep-related hypoxemia (ISRH) (nocturnal oxyhemoglobin saturation (SpO2) < 88% for 5 min or more without OSA, CSA, or OHS) Severe NH was defined as SpO2 < 90% for more than 20% of total sleep time (TST)
    3. Cardiac evaluation will be performed by transthoracic-echocardiography (TTE) TTE based on the guidelines of the device (Epiq 7, Philips Healthcare, Andover, MA, USA) with a 3.5 MHz (S5-1) transducer. Digitally stored images will analyze offline (Xcelera, Philips). Based on the guidelines, the systolic and diastolic characteristics of the left and right heart will measure as recommended. Tricuspid regurgitation velocity and other echocardiographic signs will combine to assess the probability of PH as recommended in ERS guidelines

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: Sehnaz Yildizeli, Assoc Prof; Phone Number: +905052693141; Email: drsehnazolgun@yahoo.com
• Study Contact Backup: Name: Bedrettin Yildizeli, Prof; Phone Number: +905323533521; Email: byildizeli@marmara.edu.tr

Study Locations

• Turkey
  • İstanbul, Turkey
    • Marmara University School of Medicine
    • Contact: Sehnaz Olgun Yildizeli, Assoc Prof; Phone Number: 05052693141; Email: drsehnazolgun@yahoo.com
    • Sub-Investigator: Bedrettin Yildizeli, Prof
    • Sub-Investigator: Caner Cınar, MD
    • Sub-Investigator: Halil Ataş, Prof
    • Sub-Investigator: Yüksel Peker, Prof
    • Sub-Investigator: Derya Kocakaya, Assoc Prof

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Study population will be the same in our previous which was mentioned above

Description

Inclusion Criteria:

• Previously diagnosed with CTEPH according to radiology and right heart catheterization and eligible for surgery
• Polisomnography test
• Includes both criteria above

Exclusion Criteria:

• do not volunter for study
• exitus

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
PE for CTEPH; CTEPH patients who were eligible for operation	Procedure: Pulmonary endarterectomy; removal of chronic thrombus from pulmonary arterial system
Medical treatment CTEPH; CTEPH patients who were not eligible for surgery of any reason and decided to follow up with medical treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mortality	mortality of patients who were or operated or followed up by medical treatment	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Type of Sleep-Related Breathing Disorders	Type of the SRBD after operation ar medical treatment	5 years
systolic pulmonary arterial pressure (sPAP)	Change in sPAP by transthoracic echocardiography after surgery or medical treatment	5 years

Collaborators and Investigators

• Sponsor: Marmara University
• Investigators: Principal Investigator: Sehnaz Olgun Yildizeli, Assoc Prof, ICJME

Publications and helpful links

General Publications

• Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 Jan 24;53(1):1801913. doi: 10.1183/13993003.01913-2018. Print 2019 Jan.
• Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb;137(2):376-87. doi: 10.1378/chest.09-1140. Epub 2009 Oct 16.
• Madani MM. Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: state-of-the-art 2020. Pulm Circ. 2021 May 24;11(2):20458940211007372. doi: 10.1177/20458940211007372. eCollection 2021 Apr-Jun.
• La Rovere MT, Fanfulla F, Taurino AE, Bruschi C, Maestri R, Robbi E, Maestroni R, Pronzato C, Pin M, D'Armini AM, Pinna GD. Chronic thromboembolic pulmonary hypertension: Reversal of pulmonary hypertension but not sleep disordered breathing following pulmonary endarterectomy. Int J Cardiol. 2018 Aug 1;264:147-152. doi: 10.1016/j.ijcard.2018.02.112.
• Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL, Tangredi MM; American Academy of Sleep Medicine. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012 Oct 15;8(5):597-619. doi: 10.5664/jcsm.2172.
• Cinar C, Yildizeli SO, Balcan B, Yildizeli B, Mutlu B, Peker Y. Determinants of Severe Nocturnal Hypoxemia in Adults with Chronic Thromboembolic Pulmonary Hypertension and Sleep-Related Breathing Disorders. J Clin Med. 2023 Jul 12;12(14):4639. doi: 10.3390/jcm12144639.

Study record dates

Study Major Dates

• Study Start (Estimated): December 20, 2023
• Primary Completion (Estimated): August 20, 2024
• Study Completion (Estimated): November 20, 2024

Study Registration Dates

• First Submitted: September 23, 2023
• First Submitted That Met QC Criteria: September 23, 2023
• First Posted (Actual): September 29, 2023

Study Record Updates

• Last Update Posted (Actual): October 4, 2023
• Last Update Submitted That Met QC Criteria: October 1, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Nervous System Diseases; Respiratory Tract Diseases; Apnea; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Lung Diseases; Sleep Apnea Syndromes; Hypertension; Respiratory Aspiration; Hypertension, Pulmonary
• Other Study ID Numbers: 20231009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No